Experts across the political spectrum have questioned how much society should be willing to pay for new and expensive treatments, especially if another treatment exists with a proven track record. Although it often escapes policymakers, the heart of this debate should be medical efficacy. For both the new treatment and the old, do they work? How … Continue reading →